<div id="readability-page-1"><p>Kennedy Capital Management LLC trimmed its stake in  Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 51.1% in the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 75,019 shares of the biotechnology company's stock after selling 78,468 shares during the quarter. Kennedy Capital Management LLC owned approximately 0.16% of Capricor Therapeutics worth $745,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Capricor Therapeutics</strong> alerts:</span></p></div><ul><li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li></ul><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers increased its position in  Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after purchasing an additional 3,636 shares in the last quarter.  Legal &amp; General Group Plc boosted its stake in shares of  Capricor Therapeutics by 8.4% during the 2nd quarter. Legal &amp; General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after purchasing an additional 3,205 shares during the last quarter.  Citizens Financial Group Inc. RI boosted its stake in shares of  Capricor Therapeutics by 249.2% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company's stock worth $348,000 after purchasing an additional 24,977 shares during the last quarter.  Geode Capital Management LLC raised its position in shares of  Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after buying an additional 61,701 shares during the last quarter.  Finally, Simplify Asset Management Inc. purchased a new position in shares of  Capricor Therapeutics during the second quarter valued at approximately $397,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of brokerages recently issued reports on CAPR. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Maxim Group raised their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Alliance Global Partners  reaffirmed a &#34;buy&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday. Finally, HC Wainwright raised their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, December 3rd. One investment analyst  has rated the stock with a Strong Buy rating, eight have given a Buy rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.50.</p><p><b>Check Out Our Latest Research Report on CAPR</b></p><h2>Capricor Therapeutics Price Performance</h2><p>NASDAQ CAPR opened at $28.56 on Tuesday. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The business's 50-day simple moving average is $8.01 and its 200-day simple moving average is $8.34. The firm has a market capitalization of $1.31 billion, a P/E ratio of -15.87 and a beta of 0.62. </p><p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting analysts' consensus estimates of ($0.54).  On average, equities research analysts expect that  Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year. </p><h2>Capricor Therapeutics Company Profile</h2> (Free Report)<p>Capricor Therapeutics, Inc <span>NASDAQ: CAPR<span></span></span> is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Capricor Therapeutics</li><li>Stock Average Calculator      </li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>Industrial Products Stocks Investing </li><li>3 Stocks Most Likely to Split in 2026</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CAPR

<p>Kennedy Capital Management LLC reduced its stake in Capricor Therapeutics by 51.1% in Q2. Despite this, other institutional investors increased their positions. Analysts have mixed ratings, with a consensus price target of $34.50. Capricor's stock opened at $28.56, with a market cap of $1.31 billion. The company focuses on biological therapeutics for rare disorders, with CAP-1002 in clinical development for Duchenne muscular dystrophy.</p>

Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR